IP Library Granted Patent US 11,534,108
Granted Patent B2
US 11,534,108 · App. 16/564,796 · Granted Dec 27, 2022

Screening device, method, and system for structural heart disease

Inventors: Gabriel Nallathambi (San Jose, CA); Ben Alexander (San Jose, CA); Nandakumar Selvaraj (San Jose, CA)
Assignee: VITAL CONNECT, INC.
A61B5/6801A61B5/0006A61B5/25A61B5/6823A61B7/04A61B2562/0219
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,534,108
App. No.
16/564,796
Granted
Dec 27, 2022
Kind
B2
Abstract

A wireless wearable sensor device, system, method, and non-transitory computer readable medium for screening for structural heart disease based on electrocardiogram, phonocardiogram, and/or accelerometer signals on a patient's skin surface.

Claims (53)

1. A method of screening of structural heart disease using a wearable sensor device measuring one or more leads of electrocardiogram, phonocardiogram, and accelerometer signals at chest skin surface, the method comprising:

measuring, by at least one sensor, electrocardiogram (ECG), phonocardiogram (PCG), and accelerometer (ACC) signals on a patient's skin surface and sending the ECG, PCG, and ACC signals to a processor;

executing, by the processor, an application stored in a memory to:

filter the ECG, PCG, and ACC signals to remove noise;

align the filtered ECG, PCG, and ACC signals in time, taking into account any propagation delay;

divide the measured signals into one or more sequences based on a measure of body acceleration,

wherein the dividing the measured signals into one or more sequences based on a measure of body acceleration includes the time aligned ECG, PCG, and ACC signals are divided into respective windows of arbitrary durations to obtain the one or more sequences;

screen decisions on the one or more sequences of the ECG and PCG derived features;

determine sequences of aggregate screening decisions; and

combine the aggregate screening decisions to screen for structural heart disease and output an indication of a presence of the screened structural heart disease to a display.

2. The method of claim 1 , wherein the measure of body acceleration is derived from the accelerometer signals.

3. The method of claim 1 , wherein the screening decisions includes applying a screening algorithm on the one or more sequences of the electrocardiogram and phonocardiogram derived features.

4. The method of claim 1 , wherein the screening decisions on one or more sequences of electrocardiogram and phonocardiogram derived features includes feeding each sequence individually into a sequence screening engine, wherein the sequence screening engine relies on two categories of features, including criteria for sequencing data.

5. The method of claim 4 , wherein the criteria for sequencing data segmentation specific features are derived after segmenting the PCG signals into constituent heart phases including S1, systole, S2, and diastole for each heartbeat.

6. The method of claim 4 , wherein the screening decisions on one or more sequences of electrocardiogram and phonocardiogram derived features further includes employing independently single channels of segmentation including physiological segmentation and model based segmentation to determine constituent heart stages.

7. The method of claim 6 , wherein a weighted sum of single channel are used to obtain a final position of the segmentation.

8. The method of claim 1 , further comprising directly deriving sequence specific features from the second sequence without any segmentation.

9. The method of claim 1 , wherein the combining individual decisions to screen for the structural heart disease includes aggregating the screening and fed into a sequence aggregate model to determine a final decision for the structural heart disease.

10. A method of screening of structural heart disease using a wearable sensor device measuring one or more leads of electrocardiogram, phonocardiogram, and accelerometer signals at chest skin surface, the method comprising:

measuring, by at least one sensor, electrocardiogram (ECG), phonocardiogram (PCG), and accelerometer (ACC) signals on a patient's skin surface and sending the ECG, PCG, and ACC signals to a processor;

executing, by the processor, an application stored in a memory to:

divide the measured signals into one or more sequences based on a measure of body acceleration;

screen decisions on the one or more sequences of the ECG and PCG derived features;

determine sequences of aggregate screening decisions;

combine the aggregate screening decisions to screen for structural heart disease; and

output an indication of a presence of the screened structural heart disease to a display;

wherein the screening decisions on one or more sequences of electrocardiogram and phonocardiogram derived features includes feeding each sequence individually into a sequence screening engine, wherein the sequence screening engine relies on two categories of features, including segmentation specific features and sequence specific features to screen the sequence;

wherein the screening decisions on one or more sequences of electrocardiogram and phonocardiogram derived features further includes employing independently single channels of segmentation including physiological segmentation and model based segmentation to determine constituent heart stages; and

wherein the physiological segmentation includes:

determining fiducial points in a first sequence including a peak of an R wave, and an end of a T wave for each heartbeat;

determining locations of S1 and systole (Sys) in a second sequence by using a time duration between peak of R wave (T 1 ) and end of T wave (T 2 ) of a beat from the first sequence;

determining locations of S2 and diastole (Dia) in the second sequence by using a the time duration between an end of T wave of a beat and peak of R wave of a next beat from the first sequence; and

learning the boundary between the S1 and systole, and the S2 and diastole from a training set.

11. The method of claim 6 , wherein the model based segmentation includes:

determining fiducial points in the second sequence using Hidden Markov based model (HMM); and

dividing T 1 and T 2 into heart phases of S1 and systole, and S2 and diastole, respectively; and

learning boundaries from a training set.

12. The method of claim 11 , wherein the model based segmentation further includes a subset of the heart phases.

13. A method of screening of structural heart disease using a wearable sensor device measuring one or more leads of electrocardiogram, phonocardiogram, and accelerometer signals at chest skin surface, the method comprising:

measuring, by at least one sensor, electrocardiogram (ECG), phonocardiogram (PCG), and accelerometer (ACC) signals on a patient's skin surface and sending the ECG, PCG, and ACC signals to a processor;

executing, by the processor, an application stored in a memory to:

divide the measured signals into one or more sequences based on a measure of body acceleration;

screen decisions on the one or more sequences of the ECG and PCG derived features;

determine sequences of aggregate screening decisions;

combine the aggregate screening decisions to screen for structural heart disease; and

output an indication of a presence of the screened structural heart disease to a display;

wherein the screening decisions on one or more sequences of electrocardiogram and phonocardiogram derived features includes feeding each sequence individually into a sequence screening engine, wherein the sequence screening engine relies on two categories of features, including segmentation specific features and sequence specific features to screen the sequence;

wherein the screening decisions on one or more sequences of electrocardiogram and phonocardiogram derived features further includes employing independently single channels of segmentation including physiological segmentation and model based segmentation to determine constituent heart stages; and

wherein a weighted sum of single channel detections of the physiological and model based segmentation is compared to a threshold to determine a final position of the segments.

14. The method of claim 13 , wherein features are extracted based on at least one of the output of segmentation or from the second sequence.

15. The method of claim 14 , wherein classification is performed for the segmentation specific features and sequence specific features independently using Classifier A and Classifier B, respectively,

wherein the Classifier A and the Classifier B includes machine learning algorithms including at least one of: logistic regression, support vector machines, artificial neural networks, or gradient boosting.

16. The method of claim 15 , wherein the output of the classifiers A and B are combined at a final sequence detector, based on a linear or non-linear rule to determine a decision D j .

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2024
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: VITAL CONNECT, INC.
Reel/Frame 068146/0132 →
SECURITY INTEREST Recorded Jul 5, 2024
From: VITAL CONNECT, INC.
To: TRINITY CAPITAL INC.
Reel/Frame 068146/0160 →
SECURITY INTEREST Recorded Jan 8, 2021
From: VITAL CONNECT, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 054941/0651 →
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2021
From: OXFORD FINANCE LLC
To: VITAL CONNECT, INC.
Reel/Frame 054941/0743 →
SECURITY INTEREST Recorded Apr 9, 2020
From: VITAL CONNECT, INC.
To: OXFORD FINANCE LLC
Reel/Frame 052354/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2019
From: NALLATHAMBI, GABRIEL; ALEXANDER, BEN; SELVARAJ, NANDAKUMAR
To: VITAL CONNECT, INC.
Reel/Frame 050431/0725 →
Continuity (2)
Provisional Application 62728199 · Sep 7, 2018
Related Publication 20200077951A1 · Mar 12, 2020
Cited By (1)
US 12,458,288